Metsera (NASDAQ:MTSR) Cut to Equal Weight at Wells Fargo & Company

Key Points

• Wells Fargo & Company downgraded Metsera from an "overweight" rating to an "equal weight" rating, with a price objective of $54.00, indicating a potential upside of 3.65% from its current price.
• Other analysts have also downgraded the stock, with Leerink Partners changing their rating from "strong-buy" to "hold", while Bank of America increased their price target from $45.00 to $50.00 and maintained a "buy" rating.
• Metsera has seen significant institutional investment, with companies like Alphabet Inc. and T. Rowe Price acquiring new stakes, totaling over $135 million and $78 million respectively in the first quarter.

Metsera (NASDAQ:MTSR - Get Free Report) was downgraded by Wells Fargo & Company from an "overweight" rating to an "equal weight" rating in a research report issued to clients and investors on Tuesday,Finviz reports. They presently have a $54.00 price objective on the stock. Wells Fargo & Company's price target indicates a potential upside of 3.65% from the stock's current price.

Several other equities analysts have also weighed in on the stock. Leerink Partnrs lowered shares of Metsera from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 24th. Wall Street Zen downgraded shares of Metsera from a "hold" rating to a "sell" rating in a research note on Tuesday, September 23rd. Bank of America upped their price target on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Cantor Fitzgerald restated an "overweight" rating on shares of Metsera in a research note on Wednesday, September 3rd. Finally, Guggenheim upped their price target on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $55.75.

Metsera Price Performance

Shares of MTSR stock opened at $52.10 on Tuesday. The company's fifty day simple moving average is $36.69 and its 200-day simple moving average is $30.31. Metsera has a 12 month low of $12.30 and a 12 month high of $54.47.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Institutional Investors Weigh In On Metsera

A number of hedge funds have recently made changes to their positions in the stock. Alphabet Inc. acquired a new stake in shares of Metsera in the 1st quarter valued at approximately $135,059,000. T. Rowe Price Investment Management Inc. bought a new position in Metsera in the 1st quarter valued at approximately $78,748,000. Wellington Management Group LLP bought a new position in Metsera in the 1st quarter valued at approximately $65,382,000. Alpha Wave Global LP bought a new position in Metsera in the 1st quarter valued at approximately $64,894,000. Finally, Price T Rowe Associates Inc. MD bought a new position in Metsera in the 1st quarter valued at approximately $42,395,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.